inv

Non-Invasive Diagnostic Tests for Celiac Disease

Celiac disease (CD) is an autoimmune inflammatory disease of the small intestine that is triggered in genetically susceptible persons by the ingestion of the gluten-containing grains wheat, rye, barley, and possibly oats. The condition is thought to result from the activation of both a T-cell and B-cell immune respons...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.(NASDAQ:ACCL), the leading provider of scientific businessintelligence software and services, announced today that its CFO,Rick Russo, will present at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference in New York on July 11, 2007 at10:30 a.m. ET. The conference will take place at the MandarinOriental Hotel July 10th-12...

Tercica to Present at Investment Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--Jul 2, 2007 - Tercica, Inc.(NASDAQ:TRCA) today announced that Company management will make aninvestment community presentation at the C.E. Unterberg, TowbinEmerging Growth Opportunities Conference at the Mandarin OrientalHotel in New York on Wednesday, July 11, 2007 at 4:00 p.m. Easterntime (1:00 p.m. Pacific time). A live audio webcast and slide present...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 - Genzyme Corp. (Nasdaq: GENZ)today announced the results of two new studies comparing a powderform of Renvela™ (sevelamer carbonate) to Renagel®tablets (sevelamer hydrochloride), including one trial in whichpatients received the powder form three times per day, and one inwhich it was administered once per day. Genzyme is developing Renvela...

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. today announced the results of two new studiescomparing a powder form of Renvela (sevelamer carbonate) to Renageltablets (sevelamer hydrochloride), including one trial in whichpatients received the powder form three times per day, and one inwhich it was administered once per day. Genzyme is developing Renvela in...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from aPhase II study presented for the first time at the AmericanHeadache Society (AHS) annual meeting showed that MK-0974, aninvestigational oral calcitonin gene-related peptide (CGRP)receptor antagonist, significantly improved migraine pain relieftwo hours after dosing compared to placebo, and the relief wassustained through 24 hour...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selectiveVEGF signaling inhibitor - shows over a quarter of patients aliveand progression- free at six months(1) CHICAGO, June 04, 2007 /PRNewswire/ -- Data for theinvestigational agent cediranib (AZD2171) were presented today atthe annual meeting of the American Society of Clinical Oncology(ASCO) from a study in patients with recurr...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survivalin the SPARC Phase 3 trial consistently demonstrate a reduction inrelative risk of disease progression for patients receivingsatraplatin. These analyses included prior Taxotere use,geographies, as well as presence or absence of pain. -- The twomajor causes of progression in the SPARC trial - radiologicprogression and pain prog...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

- All pre-specified subset analyses of progression-free survival inthe SPARC Phase 3 trial consistently demonstrate a reduction inrelative risk of disease progression for patients receivingsatraplatin. These analyses included prior Taxotere use,geographies, as well as presence or absence of pain. CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation and GPC Biotech AG today...

Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin

Investigational cancer drug Pertuzumab shows promising results inadvanced breast cancer when combined with Herceptin Phase IIIdevelopment initiated BASEL, Switzerland, June 4, 2007-Early clinical results fromRoche's trial of the exciting new cancer medicine pertuzumab, a HERdimerisation inhibitor, show substantial anti-tumour activity inpatients with pre-treated HER2 positive breast cance...

Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007

Leverkusen, Germany, May 31, 2007- Results from variousclinical studies including a pivotal Phase III trial in patientswith advanced hepatocellular carcinoma, or primary liver cancerwith Nexavar (sorafenib) tablets will be presented at the AnnualMeeting of the American Society of Clinical Oncology (ASCO) inChicago, USA from June 1 - 5, 2007. On this occasion a conference call for i...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

- Findings from an Otsuka Pharmaceutical Co, Ltd. Sponsored StudyPresented at the American Psychiatric Association Annual Meeting - SAN DIEGO, May 23, 2007 /PRNewswire/ -- In a six-week study inadolescents (13- 17 years old) with schizophrenia, the OtsukaPharmaceutical Co., Ltd. and Bristol-Myers Squibb Company atypicalantipsychotic aripiprazole demonstrated significant improvementcompare...

Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principalinvestigators for the COSTAR II (CObalt Chromium STent withAntiproliferative for Restenosis) trial, the pivotal study for theCoStar(R) cobalt chromium paclitaxel-eluting coronary stent,presented today the clinical trial results of the study at EuroPCR2007. The investigators confirmed that the study failed to meet itsprimary endpoint...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

-- Median time to pain progression is 66.1 weeks for thesatraplatin arm compared with 22.3 weeks for the placebo arm --Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representinga 36% reduction in the relative risk of pain progression MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/-- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG andPharmion Corporation today a...

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

- Results Presented at 160th Annual Meeting of the AmericanPsychiatric Association - SAN DIEGO, May 21, 2007 /PRNewswire-FirstCall/ -- In adults withmajor depressive disorder, adding aripiprazole to antidepressanttherapy (ADT) resulted in significant improvement in the primaryendpoint, the Montgomery- Asberg Depression Rating Scale (MADRS)Total Score. In this six-week, randomized, placebo...

FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.

Company Misrepresented Prescription PainReliever to Health Care Professionals ROCKVILLE, Md., May 10, 2007-The U.S. Food and DrugAdministration's (FDA) Office of Criminal Investigations (OCI)announced today that The Purdue Frederick Company, Inc. has agreedto pay more than $700 million to resolve criminal charges and civilliabilities in connection with...

Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass., May 21, 2007 /PRNewswire/ -- Microbia todayannounced the presentation of data from a Phase 2 study in whichlinaclotide accelerated colonic transit and improved bowel functionin patients with constipation- predominant irritable bowel syndrome(IBS-C). These data also showed linaclotide was well tolerated witha low in...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats

First Scientific Presentation for Pristiq Occurs at the 55th AnnualClinical Meeting of the American College of Obstetricians andGynecologists COLLEGEVILLE, Pa., May 09, 2007 /PRNewswire-FirstCall/ -- WyethPharmaceuticals, a division of Wyeth , presented results from thefirst Phase 3 studies evaluating Pristiq(TM) (desvenlafaxine) forthe treatment of moderate-to-severe vasomotor symptoms (...

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007

JERSEY CITY, N.J.--(BUSINESS WIRE)--May 4, 2007 - Lux Biosciences,Inc., a privately held biotechnology company specialized in thefield of ophthalmic diseases, announced today that the company'snext-generation calcineurin inhibitor, LX211, is the subject of twopresentations at the Association for Research in Vision andOphthalmology (ARVO) annual meeting, being held May 6-10 in FortLauderdale...

Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study

Most Patients Achieved at Least 75 Percent Improvement in PsoriasisSigns and Symptoms at Week 12; in Four of Five Dosing Groups, MoreThan Half Achieved 90 Percent Improvement ABBOTT PARK, Ill., May 04, 2007 /PRNewswire-FirstCall/ -- NewPhase II study results show Abbott's investigational treatment,ABT-874, reduced psoriasis symptoms significantly in the majorityof patients treated. At 12...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ --Alpharma Inc. , a leading global specialty pharmaceutical companythrough its Pharmaceuticals Division, this week presented positiveresults of a pharmacokinetic study of its investigationalabuse-deterrent, extended-release opioid at the 26th annualscientific meeting of the American Pain Society in Washington, D.C.The data demonstrat...

New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death

Worldwide pivotal phase III study in women with recurrent ovariancancer underway SYDNEY, Australia and WASHINGTON, May 01, 2007/PRNewswire-FirstCall/ -- A new study further supports the uniquemechanism of action of phenoxodiol, an investigational drug beingstudied for the treatment of ovarian cancer. The drug appears towork by targeting a certain tumor-specific protein, which triggersa s...

Northfield Laboratories Investor Update

EVANSTON, Ill.--(BUSINESS WIRE)--Apr 26, 2007 - NorthfieldLaboratories Inc. (Nasdaq: NFLD) announced today that its contractresearch organization has informed the Company that the report ofthe summary data from its pivotal Phase III trauma trial withPolyHeme(R), the Company's human-hemoglobin based oxygen-carryingred cell substitute, will not be complete until May. About Northfield Labora...

Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - AcordaTherapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr.Lauren Krupp, Professor of Neurology at Stony Brook University,will present data from Acorda's Phase 3 clinical trial ofFampridine-SR in multiple sclerosis at their analyst and investorreception on May 2, 2007. This reception will follow a presentationof this data at the Ameri...

Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease

CAMBRIDGE, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. announced today that a recently completed study ofRenvela(TM) (sevelamer carbonate) achieved its primary endpoint,demonstrating a statistically significant reduction in serumphosphorus for hyperphosphatemic patients with chronic kidneydisease who are not on dialysis. Patients treated with Renvela also achieved...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-sponsored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breakerpresentation at the 42nd Annual Meeting of the European Associationfor the Study of the Liver (EASL), researchers today presented datafrom a planned interim analysis of the PROVE 1 clinical trial,which is the first trial to evaluate short-duration therapy withthe investigational hepatitis C protease inhibitor telaprevir (TVR,...

Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)

BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New datasupporting the clinical development of telaprevir (VX-950), one ofthe most advanced investigational oral protease inhibitors for thetreatment of hepatitis C virus (HCV) infection, will be presentedat the 42nd Annual Meeting of the European Association for theStudy of the Liver (EASL) in Barcelona this week. In total, nineabstracts re...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

52-Week Trial Maintained Improvement in Personal and SocialPerformance COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ --Longer-term treatment with INVEGA(TM) (paliperidone)Extended-Release Tablets, a new once daily oral medication forschizophrenia, helped many patients effectively control theirsymptoms and maintain their improvements in personal and socialfunctioning....

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest SafetyProgram of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorablefindings of the investigational drug Cleviprex(TM) (clevidipine)compared to current intravenous antihypertensive agents incontrolling perioperative hypertension -- a potentially harmfulelevation in blood pressure j...